Clinical, imaging and blood biomarker outcomes in a Phase 3 clinical trial of tau aggregation inhibitor hydromethylthionine mesylate in mild cognitive impairment and mild to moderate dementia due to Alzheimer’s disease

Key Points

This research aims to evaluate the clinical, imaging, and biomarker outcomes of hydromethylthionine mesylate in subjects with mild cognitive impairment and dementia associated with Alzheimer's disease.
Conducted a Phase 3 clinical trial
Administered hydromethylthionine mesylate at a dosage of 16 mg/day
Monitored clinical endpoints and imaging outcomes over 52 weeks
Assessed safety and tolerability of the treatment
HMTM halted neurodegeneration and decreased grey matter atrophy by 52 weeks
Significant clinical separation in mild cognitive impairment was observed at 78 and 104 weeks
The control arm’s symptomatic activity affected outcomes at 52 weeks
HMTM demonstrated a benign safety profile and was well tolerated

Phase 3 trial examines clinical outcomes of HMTM in mild cognitive impairment and mild to moderate dementia, indicating potential treatment benefits.

No abstract yet. The journal hasn't published one we can show.

No takes yet. Share an insight, caveat, or question.

Wischik et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Share